Advances in research of iRGD peptide cooperating with oxaliplatin in reversing colorectal cancer drug resistance

doi:10.3877/cma.j.issn.2095-3224.2018.06.013

Abstract

Abstract:

Colorectal cancer is a common malignant tumor in the world. Oxaliplatin is the third-generation platinum drug and commonly used in colorectal cancer, its chemotherapy-based regimen has become the standard for chemotherapy for colorectal cancer. An important reason of colorectal cancer chemotherapy failure is the development of drug resistance of tumor cells to chemotherapy drugs. Recent studies have found that the combination of targeting modifiers and chemotherapeutic drugs can increase the local concentration of chemotherapeutic drugs in the tumor tissue. iRGD peptide, as a mediator in combination with chemotherapeutic drugs, potentiates the chemotherapeutic effect, intravascular injection of a chemotherapeutic drug modified with the iRGD peptide can cause the chemotherapeutic drug to bind to the tumor blood vessel and spread to the extravascular tumor mass. In this paper, advances in research of iRGD peptide cooperating with oxaliplatin in reversing colorectal cancer drug resistance are reviewed in detail.

Key words: Colorectal neoplasms, Drug Resistance, Neoplasm, iRGD peptide, Oxaliplatin, Research progress

Zhongwei Ji, Yuxi Yang, Shenglong Li, Bomiao Zhang, Yunlong Li, Yuenan Huang. Advances in research of iRGD peptide cooperating with oxaliplatin in reversing colorectal cancer drug resistance[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2018, 07(06): 572-575.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2018.06.013

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2018/V07/I06/572

References 23

[1]	McQuade RM, Stojanovska V, Bornstein JC. Colorectal cancer chemotherapy: the evolution of treatment and new approaches [J].Current medicinalchemistry, 2017, 24(15): 1537-1557.
[2]	Raymond E, Faivre S, Chaney S, et al. Cellular and molecular pharmacology of oxaliplatin [J]. Molecular Cancer Therapeutics, 2002, 1(3): 227-235.
[3]	Mort R, Mo L, McEwan C, et al. Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer [J]. British Journal of Cancer, 2003, 89(2): 333-337.
[4]	Usanova S, Piée-Staffa A, Sied U, et al.Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression [J].Mol cancer, 2010, 9: 248.
[5]	Stordal B, Davey R.ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair [J].Cancer Chemother Pharmacol, 2009, 63(4): 661-672.
[6]	Stiegelbauer V, Perakis S, Deutsch A, et al. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer [J]. World J Gastroenterol, 2014, 20(33): 11727-11735.
[7]	Kjersem JB, Ikdahl T, Lingjaerde OC, et al. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment [J]. Mol Oncol, 2014, 8(1): 59-67.
[8]	Beretta GL, Benedetti V, Cossa G, et al. Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin [J].Biochem Pharmacol, 2010, 79(8): 1108-1117.
[9]	Sugahara KN, Teesalu T, Karmali PP, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors [J].Cancer Cell, 2009, 16(6): 510-520.
[10]	Ye Y, Zhu L, Ma Y, et al. Synthesis and evaluation of new iRGD peptide analogs for tumor optical imaging [J]. Bioorg Med Chem Lett, 2011, 21(4): 1146-1150.
[11]	Teesalu T, Sugahara KN, Ruoslahti E. Tumor-penetrating peptides [J]. Frontiers in oncology, 2013, 3: 216.
[12]	Alberici L, Roth L, Sugahara KN, et al. De novo design of a tumor-penetrating peptide [J]. Cancer Research, 2013, 73(2): 804-812.
[13]	Teesalu T, Sugahara KN, Kotamraju VR, et al.C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration [J].Proc Natl Acad Sci U S A., 2009, 106(38): 16157-16162.
[14]	Zanuy D, Kotla R, Nussinov R, et al.Sequence dependence of C-end rule peptides in binding and activation of neuropilin-1 receptor [J].J Struct Biol, 2013, 182(2): 78-86.
[15]	Prud′homme GJ, Glinka Y.Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity [J].Oncotarget, 2012, 3(9): 921-939.
[16]	Pang HB, Braun GB, Friman T, et al.An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability [J].Nat Commun, 2014, 5: 4904.
[17]	Ruoslahti E.Tumor penetrating peptides for improved drug delivery [J].Adv Drug Deliv Rev,2017, 110-111: 3-12.
[18]	Sugahara KN, Teesalu T, Karmali PP, et al.Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs[J].Science, 2010, 328(5981): 1031-1035.
[19]	Thayanithy V, Dickson EL, Steer C, et al.Tumor-stromal cross talk: direct cell-to-cell transfer of oncogenic microRNAs via tunneling nanotubes [J].Trans Res, 2014, 164(5): 359-365.
[20]	Connor Y, Tekleab S, Nandakumar S, et al.Physical nanoscale conduit-mediated communication between tumour cells and the endothelium modulates endothelial phenotype [J].Nat commun, 2015, 6: 8671.
[21]	Sugahara KN, Braun GB, de Mendoza TH, et al.Tumor-penetrating iRGD peptide inhibits metastasis [J].Mol Cancer Ther, 2015, 14(1): 120-128.
[22]	Maione F, Capano S, Regano D, et al.Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice [J]. J Clin Invest, 2012, 122(5): 1832-1848.
[23]	Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases [J].Nat Rev Drug Discov, 2011, 10(6): 417-427.

Please choose a citation manager

Content to export